Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease

Abstract

Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.